Unknown

Dataset Information

0

COVID-19 and ANCA-associated vasculitis - recommendations for vaccine preparedness and the use of rituximab.

ABSTRACT:

SUBMITTER: Bruchfeld A 

PROVIDER: S-EPMC8136000 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
| S-EPMC3137658 | biostudies-literature
Unknown Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
| S-EPMC7612177 | biostudies-literature
Unknown Plasma exchange with COVID-19 convalescent plasma in a patient with severe ANCA-associated vasculitis and COVID-19 pneumonia after rituximab therapy.
| S-EPMC8244539 | biostudies-literature
Unknown Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic.
| S-EPMC7431342 | biostudies-literature
Unknown Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
| S-EPMC4378104 | biostudies-literature
Unknown PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
| S-EPMC8311572 | biostudies-literature
Unknown The impact of COVID-19 pandemic on patients with ANCA associated vasculitis
| S-EPMC7543954 | biostudies-literature
Unknown ANCA Vasculitis Induction Management During the COVID-19 Pandemic.
| S-EPMC8373584 | biostudies-literature
Unknown Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
| S-EPMC7937025 | biostudies-literature
Unknown SARS-CoV-2 vaccine response in ANCA associated vasculitis patients.
| S-EPMC8664608 | biostudies-literature